CardioGenics Holdings (CardioGenics Holdings) EBIT per Share : $-0.01 (TTM As of Jan. 2016)

View and export this data going back to 2004. Start your Free Trial

What is CardioGenics Holdings EBIT per Share?

CardioGenics Holdings's EBIT per Share for the three months ended in Jan. 2016 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2016 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for CardioGenics Holdings's EBIT per Share or its related term are showing as below:

CGNH's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: -1.7
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

CardioGenics Holdings's EBIT for the three months ended in Jan. 2016 was $-0.20 Mil.

CardioGenics Holdings EBIT per Share Historical Data

The historical data trend for CardioGenics Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardioGenics Holdings EBIT per Share Chart

CardioGenics Holdings Annual Data

Trend

Jul06

Jul07

Jul08

Oct09

Oct10

Oct11

Oct12

Oct13

Oct14

Oct15

EBIT per Share

Get a 7-Day Free Trial

-0.10

-0.02

-0.04

-0.02

-0.01

CardioGenics Holdings Quarterly Data
	Apr11	Jul11	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Apr13	Jul13	Oct13	Jan14	Apr14	Jul14	Oct14	Jan15	Apr15	Jul15	Oct15	Jan16
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

CardioGenics Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

CardioGenics Holdings's EBIT per Share for the fiscal year that ended in Oct. 2015 is calculated as

	EBIT per Share		(A: Oct. 2015 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.772	/	94.424
=	-0.01

CardioGenics Holdings's EBIT per Share for the quarter that ended in Jan. 2016 is calculated as

	EBIT per Share		(Q: Jan. 2016 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.201	/	116.716
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

CardioGenics Holdings (OTCPK:CGNH) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

CardioGenics Holdings EBIT per Share Related Terms

Thank you for viewing the detailed overview of CardioGenics Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CardioGenics Holdings (CardioGenics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CardioGenics Holdings Inc (OTCPK:CGNH) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

6295 Northam Drive, Unit 8, Mississauga, ON, CAN, L4V 1W8

Website

http://www.cardiogenics.com

CardioGenics Holdings Inc is a biotechnology company. It is engaged in the development and commercialization of diagnostic test products for the In-Vitro Diagnostics (IVD) testing market. The company's objective is to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies. Its products include QL Care Analyzer, Immunoassay Tests, and Paramagnetic Beads. The business activity is primarily carried out through the region of Canada.

CardioGenics Holdings (CardioGenics Holdings) Headlines

No Headlines